NCT05568095

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

← 임상시험 허브

레지스트리 요약

진행 상태: 완료 (COMPLETED)
질환/조건: Advanced Upper Gastrointestinal Tract Adenocarcinoma
시험 유형: 중재 연구 (INTERVENTIONAL)
단계: Phase 3
목적: 치료
중재 유형: 약물
개입·치료: Domvanalimab, Zimberelimab, Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Nivolumab
Lead Sponsor: Arcus Biosciences, Inc. (산업계)

캐시 시각: 2026-09-04 00:21:23

ClinicalTrials.gov에서 보기

요약

This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) monoclonal antibody domvanalimab, the anti programmed cell death protein 1 (PD-1) monoclonal antibody zimberelimab, and multiagent chemotherapy versus the anti PD-1 monoclonal antibody nivolumab and multiagent chemotherapy in the first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.

문의

이 시험 기반 리포트·메디컬라이팅이 필요하시면 문의해 주세요.

리포트 문의 메디컬라이팅 문의 맞춤 리서치 리포트